What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Pivot Points

Score

-1.25

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 93 4.0 0.33% 0.44% 11.5% -3.2% 132.0%
SHORT 95 5.7 0.41% 0.57% 2.5% -3.3% -123.5%

Summary

Technical Analysis

Opthea (OPT.AX)


Indicator:

PIVOT POINT


Signal Strength: MEDIUM
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.


Opthea (ASX:OPT) current pivot point is: $ 2.96.
The current resistance levels are:
(R1) $3.04
(R2) $3.13
(R3) $3.21

The current support levels are:
(S1) $2.87
(S2) $2.79
(S3) $2.7



Pivots Points are significant levels chartists can use to determine directional movement support and resistance. Pivot Points use the prior period’s high low and close to formulate future support and resistance. In this regard Pivot Points are predictive or leading indicators.

Calculation: Pivot Points:
1) Pivot Point (P) = (High + Low + Close)/3;
2) Support 1 (S1) = (P x 2) – High; Support 2 (S2) = P - (High - Low);
3) Resistance 1 (R1) = (P x 2) – Low Resistance 2; (R2) = P + (High - Low);


PROFILE: Opthea (OPT.AX)


Stock Exchange: ASX
Company: Opthea
Ticker Codes: | OPT.AX | ASX:OPT |

About Opthea (ASX:OPT):

Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.

Top 10:

Pivot Points

Download
Company Close Change(%) Volume Value Signal
LNG Liquefied Natural Gas 0.21 5.1 2,729,105 0 BEARISH
GTN GTN Resources 0.7 3.7 7,121 0 BEARISH
MSB Mesoblast 1.9 2.2 4,456,404 -0.01 BEARISH
GAP Gale Pacific 0.27 1.9 262,955 0 BEARISH
EML Emerchants 4.48 1.8 4,996,325 -0.06 BEARISH
AKP Audio Pixels Holdings 16.1 1.3 4,258 -0.12 BEARISH
AYS Amaysim Australia 0.42 1.2 80,507 0 BEARISH
OZL Oz Minerals 10.52 1.1 1,778,879 0 BEARISH
NUF Nufarm 5.02 1 2,124,167 -0.01 BEARISH
SGF SG Fleet 2.68 0.8 338,167 -0.01 BEARISH